Try a new search

Format these results:

Searched for:



Total Results:


Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma

McBride, Sean; Sherman, Eric; Tsai, C Jillian; Baxi, Shrujal; Aghalar, Jahan; Eng, Juliana; Zhi, Wanqing Iris; McFarland, Daniel; Michel, Loren Scott; Young, Robert; Lefkowitz, Robert; Spielsinger, Daniel; Zhang, Zhigang; Flynn, Jessica; Dunn, Lara; Ho, Alan; Riaz, Nadeem; Pfister, David; Lee, Nancy
PURPOSE:The objective response rate (ORR) for single-agent anti-programmed death receptor 1 (anti-PD-1) therapy is modest in patients with metastatic or recurrent head and neck squamous cell carcinoma (HNSCC). We aimed to test whether radiotherapy may act synergistically with anti-PD-1 therapy to improve response through the abscopal effect. PATIENTS AND METHODS:We conducted a single-center, randomized, phase II trial of nivolumab (anti-PD-1 therapy) versus nivolumab plus stereotactic body radiotherapy (SBRT) in patients with metastatic HNSCC. Patients had at least two metastatic lesions: one that could be safely irradiated and one measurable by RECIST version 1.1. Patients were randomly assigned (1:1), stratified by human papillomavirus status, to nivolumab (3 mg/kg intravenously every 2 weeks) or nivolumab (same dose) plus SBRT (9 Gy × 3) to 1 lesion. The primary end point was ORR in nonirradiated lesions, which was assessed by RECIST in patients with at least one available set of on-treatment images; safety was assessed in a per-protocol population. RESULTS:= .70). CONCLUSION:We found no improvement in response and no evidence of an abscopal effect with the addition of SBRT to nivolumab in unselected patients with metastatic HNSCC.
PMID: 32822275
ISSN: 1527-7755
CID: 5052902

Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial

Feldman, Darren R; Ged, Yasser; Lee, Chung-Han; Knezevic, Andrea; Molina, Ana M; Chen, Ying-Bei; Chaim, Joshua; Coskey, Devyn T; Murray, Samuel; Tickoo, Satish K; Reuter, Victor E; Patil, Sujata; Xiao, Han; Aghalar, Jahan; Apollo, Arlyn J; Carlo, Maria I; Motzer, Robert J; Voss, Martin H
BACKGROUND:We previously reported on a phase 2 study of everolimus plus bevacizumab across various nonclear cell renal cell carcinoma (nccRCC) histologies and observed encouraging activity among patients with papillary RCC (pRCC) and unclassified RCC (uRCC) with a major papillary component. We subsequently expanded the study to enroll additional patients with pRCC variants. METHODS:Everolimus plus bevacizumab was administered at standard doses until disease progression or intolerance to therapy. The primary endpoint was the 6-month progression-free survival (PFS) rate; secondary endpoints included objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and safety. Correlative analyses included next-generation sequencing (NGS) from tumor and germline across >341 genes of interest. RESULTS:In addition to 19 patients with pRCC variants in the original cohort, 20 patients with similar features were enrolled on the expansion cohort (uRCC with papillary features [n = 24], pRCC [n = 14], and translocation-associated RCC with papillary features [n = 1]). Among 37 evaluable patients, the 6-month PFS rate was 78%, the median PFS was 13.7 months (95% CI, 10.8-16.4 months), and the ORR was 35%. With a median follow-up of 17.6 months, the median OS was 33.9 months (95% CI, 23.3-71.9). Tolerance was consistent with prior reports for everolimus plus bevacizumab. NGS results (n = 33) identified responses in patients with a wide spectrum of genomic alterations, including ARID1A, FH, and MET mutations. CONCLUSION:The expansion cohort results confirm robust activity of everolimus plus bevacizumab in metastatic pRCC variants, supporting this regimen as a standard option for this patient population.
PMID: 32975815
ISSN: 1097-0142
CID: 5052912

Mandatory cognitive screening in hospitalized elderly people: are we missing the diagnosis? [Letter]

Chang, Evelyn; Jacoby, Sari; Wang, Janice; Aghalar, Jahan; Hussain, Roshan; Pekmezaris, Renee; Wolf-Klein, Gisele P
PMID: 19392972
ISSN: 1532-5415
CID: 2964572